RESUMEN
Dronedarone is a new antiarrhythmic drug for the treatment of atrial fibrillation. This study investigated the complexation of dronedarone hydrochloride with ßcyclodextrin (ß-CD) and 2hydroxypropilßCD (HP-ß-CD) using three different techniques. The complexes in the solid state were characterized by DSC, TGA, PXRD, FT-IR, SEM and 1H NMR, demonstrating the formation of the inclusion complexes and exhibiting different properties from the pure drug. Its aqueous solubility increased about 4.0-fold upon complexation with ß-CD and HP-ß-CD. The dissolution rate of the drug was notably improved in all tested physiological pH values from 1.2 to 6.8 in the presence of both cyclodextrins. Furthermore, an in vitro cytotoxic assay revealed that the inclusion complexes could reduce the cytotoxic effects of the drug on 3T3 cells. The overall results suggest that the inclusion complexes with ß-CD and HP-ß-CD may be potentially useful in the preparation of novel pharmaceutical formulations containing dronedarone hydrochloride.
Asunto(s)
Antiarrítmicos/química , Dronedarona/química , beta-Ciclodextrinas/química , 2-Hidroxipropil-beta-Ciclodextrina/química , Células 3T3 , Animales , Antiarrítmicos/síntesis química , Antiarrítmicos/farmacología , Supervivencia Celular/efectos de los fármacos , Dronedarona/síntesis química , Dronedarona/farmacología , Composición de Medicamentos , Liofilización , Ratones , Microscopía Electrónica de Rastreo , Solubilidad , Espectroscopía Infrarroja por Transformada de Fourier , Termogravimetría , Difracción de Rayos XRESUMEN
Liquid formulations can be used in children of different ages by varying the volume of the administered dose in order to ensure an exact dosage. The aim of this work was to develop and to optimize a safe liquid atenolol formulation and to carry out the corresponding chemical and microbiological stability studies. A Plackett-Burman design was used to determine the factors that could be critical in the development of the formulations, and a central composite design was used to determine the optimal working conditions. As a result of these analyses, three formulations were selected and their stability studied in three storage conditions, 4, 25, and 40°C. After 6 months of stability testing, the optimal systems showed no pH change or atenolol loss; however, only glycerin-based formulations showed no microbial development. These systems, employing excipients in a range that the EMA has recommended, showed chemical and microbiological stability for at least 6 months even at the worst storage conditions.
Asunto(s)
Atenolol/síntesis química , Excipientes/síntesis química , Administración Oral , Antiarrítmicos/administración & dosificación , Antiarrítmicos/síntesis química , Atenolol/administración & dosificación , Niño , Composición de Medicamentos , Estabilidad de Medicamentos , Excipientes/administración & dosificación , Humanos , Soluciones Farmacéuticas/administración & dosificación , Soluciones Farmacéuticas/síntesis químicaRESUMEN
Two new potential impurities of antiarrhythmic drug substance Dronedarone Hydrochloride together with debutyldronedarone were detected by LC-MS analysis during process development. A successful synthetic strategy for the synthesis of these potential impurities was developed facilitating the access to new impurity reference standards. Their synthesis and characterization are discussed in detail. The availability of these impurity standards allowed cost reduction through the increase of process control.
Asunto(s)
Amiodarona/análogos & derivados , Antiarrítmicos/análisis , Antiarrítmicos/síntesis química , Amiodarona/análisis , Amiodarona/síntesis química , Técnicas de Química Analítica/métodos , Cromatografía Liquida/métodos , Cromatografía en Capa Delgada , Dronedarona , Contaminación de Medicamentos , Diseño de Fármacos , Hidrógeno/química , Espectroscopía de Resonancia Magnética/métodos , Espectrometría de Masas/métodos , Espectrometría de Masa por Ionización de Electrospray , Espectroscopía Infrarroja por Transformada de FourierRESUMEN
A practical and efficient procedure for the enantioselective synthesis of mexiletine analogues with use of 10% of spiroborate ester 6 as chirality transfer agent is presented. A variety of mexiletine analogues were prepared in good yield with excellent enantioselectivities (91-97% ee) from readily available starting materials. The developed methodology was also successfully applied for the synthesis of novel beta-amino ethers containing thiophenyl and pyridyl fragments.
Asunto(s)
Antiarrítmicos/síntesis química , Éteres/síntesis química , Mexiletine/síntesis química , Piridinas/química , Tiofenos/química , Boranos/química , Ésteres/química , Mexiletine/análogos & derivados , Modelos Químicos , EstereoisomerismoRESUMEN
A set of potential Class III antiarrhythmic agents of structure p-HOOC-R-CO-NH-C(6)H(4)-CO-X-C(2)H(5)-N(C(2)H(5))(2) were isolated as crystalline solids of the amide and ester derivatives, I: succinylprocainamide (X=-NH-, R=-C(2)H(4)-); II: succinylprocaine (X=-O-, R=-C(2)H(4)-); III: maleylprocainamide (X=-NH-, R=-C(2)H(2)-) and IV: maleylprocaine (X=-O-, R=-C(2)H(2)-). Although compounds I-IV exhibit similar solution properties (i.e. acid-base speciation, with zwitterionic (+-) to neutral (00) form ratios higher than 10(4)), aqueous solubility of -NH- derivatives is significantly higher than that of -O- derivatives and also, solvent effects on solubility (i.e. the change of water by ethanol) is clearly different in both series. Solution and solid-state properties of I-IV were characterized to account for the observed differences. Results indicate that procainamide derivatives I and III crystallizes as (+-)(s) but procaine derivatives II and IV as (00)(s). Besides, I is anhydrous but II-IV are hydrates. Aqueous solubility and solvent effect on solubility are controlled by the intrinsic solubility of the species (+-) in I and III and (00) in II and IV. The rise of hydrophilicity of species (00) due to the structural change from -O- to -NH- would determine the change in the structure of the precipitating crystals from (00)(s) to (+-)(s). Solid structure (zwitterionic or neutral), as well as composition (anhydrous or hydrated) may be recognized as the main factors in determining the rank of aqueous solubility of the set: (+-)>(+-.H(2)O)>(00.H(2)O).
Asunto(s)
Antiarrítmicos/química , Procainamida/química , Procaína/química , Antiarrítmicos/síntesis química , Radioisótopos de Carbono , Cristalización , Análisis Diferencial Térmico , Espectroscopía de Resonancia Magnética , Peso Molecular , Procainamida/síntesis química , Procaína/síntesis química , Solubilidad , Soluciones , Espectroscopía Infrarroja por Transformada de Fourier , Termogravimetría , Agua/análisisRESUMEN
O emprego da catalise de transferencia de fase substituindo uma ou mais etapas da sintese de um farmaco, pode ser um recurso vantajoso sob o ponto de vista tecnologico. Empregando na sintese de importantes farmacos que sao a dicicloverina, caramifeno e amiodarona, a catalise de transferencia de fase revelou-se muito vantajosa na sintese dos dois primeiros. A dicicloverina e o caramifeno tiveram suas rotas de obtencao verticalizadas, com bons resultados e custos bem mais baixos quando comparados com os atualmente adquiridos no exterior. Ficou evidente que a catalise de transferencia de fase pode ser aplicada com sucesso na producao destes e outros farmacos em associacao com tecnicas ja conhecidas com otimos resultados